Search Results

You are looking at 1 - 1 of 1 items for

  • Author: María Dolores Rodríguez Arnao x
Clear All Modify Search
María Dolores Rodríguez Arnao Pediatric Endocrinology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for other papers by María Dolores Rodríguez Arnao in
Google Scholar
PubMed
Close
,
Amparo Rodríguez Sánchez Pediatric Endocrinology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for other papers by Amparo Rodríguez Sánchez in
Google Scholar
PubMed
Close
,
Ignacio Díez López Hospital Universitario Araba, Araba/Alava, Spain

Search for other papers by Ignacio Díez López in
Google Scholar
PubMed
Close
,
Joaquín Ramírez Fernández Hospital Universitario Príncipe de Asturias, Oviedo, Spain

Search for other papers by Joaquín Ramírez Fernández in
Google Scholar
PubMed
Close
,
Jose Antonio Bermúdez de la Vega Centro Nuevas Tecnologias, Sevilla, Spain

Search for other papers by Jose Antonio Bermúdez de la Vega in
Google Scholar
PubMed
Close
,
Diego Yeste Fernández Hospital Vall d’Hebrón, Barcelona, Spain

Search for other papers by Diego Yeste Fernández in
Google Scholar
PubMed
Close
,
María Chueca Guindulain Complejo Hospitalario de Navarra, Pamplona, Spain

Search for other papers by María Chueca Guindulain in
Google Scholar
PubMed
Close
,
Raquel Corripio Collado Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain

Search for other papers by Raquel Corripio Collado in
Google Scholar
PubMed
Close
,
Jacobo Pérez Sánchez Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain

Search for other papers by Jacobo Pérez Sánchez in
Google Scholar
PubMed
Close
,
Ana Fernández González Merck S.L.U., Madrid, Spain

Search for other papers by Ana Fernández González in
Google Scholar
PubMed
Close
, and
ECOS Spain Study Collaborative Investigator Group
Search for other papers by ECOS Spain Study Collaborative Investigator Group in
Google Scholar
PubMed
Close

Background

Non-adherence to r-hGH treatments occurs in a variable percentage of subjects. One problem found when evaluating adherence is the great variability in methods of detection and definitions utilized in studies. This study assessed the level of adherence in subjects receiving r-hGH with the easypod™ electronic device.

Methods

National, multicenter, prospective and observational study involving 238 subjects (144 with GH deficiency (GHD), and 86 with small for gestational age (SGA), 8 with Turner Syndrome), who received r-hGH with easypod™ for at least 3 months before inclusion. The follow-up period was 4 years.

Results

Overall adherence was 94.5%; 97.5% after 6 months, 95.3% after 1 year, 93.7% after 2, 94.4% after 3 and 95.5% after 4 years of treatment. No differences in adherence were observed between prepubertal and pubertal groups and GHD and SGA groups. Change in height after 1 and 2 years, change in height SDS after 1 and 2 years, HV after 1 year, HV SDS after at 1 and 4 years, change in BMI after 1 year and change in BMI SDS at 1 and 2 years showed significant correlation with adherence. No significant differences in adherence according to IGF-I levels were found in follow-up visits or between groups.

Conclusions

The easypod™ electronic device, apart from being a precise and objective measure of adherence to r-hGH treatment, allows high compliance rates to be achieved over long periods of time. Adherence significantly impacts growth outcomes associated with r-hGH treatment.

Open access